| Literature DB >> 36051856 |
Yaung Kwee1, Yiqun Zhou2, Mochamad Zakki Fahmi3,4, Madhuri Sharon5, Alfinda Novi Kristanti3.
Abstract
Viral infection is a globally leading health issue. Annually, new lethal RNA viruses unexpectedly emerged and mutated threatening health and safety. Meanwhile, it is urgent to explore novel antiviral agents, which, however, takes years to be clinically available. Nonetheless, the development of carbon dots (CDs) in the past 20 years has exhibited their vast application potentials and revealed their promising capacity as future antiviral agents considering their versatile properties and significant antiviral responses. Thus, CDs have been widely investigated as an alternative of traditional chemotherapy for inhibiting viral infection and replication in vitro. Meanwhile, attempts to apply CDs to in vivo systems are in high demand. In this review, recent developments of CDs-based antiviral therapies are systematically summarized. Furthermore, the role of CDs in photodynamic inactivation to kill viruses or bacteria is briefly discussed. © The author(s).Entities:
Keywords: RNA virus; antiviral therapy; carbon dots; nanomedicine; virus infection treatment
Mesh:
Substances:
Year: 2022 PMID: 36051856 PMCID: PMC9428922 DOI: 10.7150/ntno.73918
Source DB: PubMed Journal: Nanotheranostics ISSN: 2206-7418
Figure 2A graphitic illustration of conjugating CBBA to CDs and mechanism of viral entry inhibition. Reprinted with the permission of the reference 26.
Figure 3Mechanism of inhibition of viral entry by 4-aminophenylboronic acid hydrochloride derived CDs. Reprinted with permission from the reference 53.
Figure 4The graphical abstract framework of the prepared BZM-CDs to block viral infectivity. Reproduced with the permission from the reference 54.
Figure 5The schematic representation of the synthetic process of APBA-CDs via carbonization and function of APBA-CDs in blocking HIV-1 infection to MOLT-4 cells. Reprinted with permission from the reference 55.
Figure 6Mechanism of viral inhibition of cationic curcumin-derived CDs. Reprinted with permission from the reference 57.
Figure 7(A) The schematic diagram of the one-step synthesis of Cur-CDs. (B) The general abstract framework of combating viruses with Cur-CDs. Reprinted with permission from the reference 59.
Figure 8(A) CDs inhibition activities of HSV-1 on A549. (B) Vero cells at varied concentrations. (C) Morphological characteristics of CD effects. Reproduced with permission from the reference 53.
Figure 9Graphical illustration of viral microRNAs inhibition by CD-interposed drug-loading of LNA for viral therapy. Reproduced with permission from the reference 66.
Figure 10(A) The broad-spectrum antiviral efficiency of Gly-CDs. Separate incubation of both Vero and PK-15 cells with Gly-CDs at different concentrations of 0.15, 0.30, 0.60, and 0.90 mg mL-1 for 12 and 24 h. (B) Cellular ROS levels in PPRSV infected MARC-145 cells post different treatments. The cell group shows normal cells not treated by either Gly-CDs or PRRSV. The mock group exhibits the PRRSV-infected cells in the absence of Gly-CDs. The Gly-CDs group indicates the PRRSV-infected cells treated with Gly-CDs. Scale bar = 100 µm. Reprinted with permission from the reference 67.
Figure 11The reverse transcriptase inhibitor-conjugated GQDs as a promising therapeutic candidate for HIV treatment. Reprinted with permission from the reference 76.
Carbon dots or other NPs developed for antiviral activities
| CDs | Precursors/Routes | Size, morphology, toxicity, and IC50 | Cells/Virus | Purpose | Reference |
|---|---|---|---|---|---|
| PBA-CDs | Boronic acid/ | •Size diameters = 332±60 nm, 55 ±1nm, 96 ± 1nm, | •A549 cells & Vero cells/ | •For stopping viral attachment and entry. |
|
| CCM-CDs | Citric acid/ | •Diameter = 1.5 ± 0.3 nm | •Vero cells/ | •For inhibiting viral entry |
|
| Young barley leaf-derived B-CDs | Citric acid/ | •Size in diameter = 1.9 nm | •Hela cells & | •For evaluating bioimaging and antiviral effects |
|
| Citric acid modified by boronic acid CDs | Carboxyl phenylboronic acid (CBBA)/ | •Diameter = 2.8 nm - 6.2 nm | •MT4 and MOLT-4 cells/ | •For inhibiting HIV infection |
|
| BZM-CDs | Hydrothermal | •Average size = 4.4 ± 0.6 nm | •BHK-21 cells & Vero cells/ | •For blocking the viral infection |
|
| Ethylenediamine + citric acid (CQDs) | Boronic acid/ | •Particle size = 6.5 ± 0.2 nm | •Huh-7 cells/ | •For inhibiting viral replication. |
|
| Citric acid and ethylene diamine (CQDs) | Streptavidin/ | •Particle size = 4 - 5nm | •HIV-1 | •For assessing HIV-1 p24 antigen on improved models |
|
| Cur-CQDs | Pyrolysis | •Mean diameter = 4.8 ± 0.8 nm | •RD cells/ | •For inhibiting EV71 infection |
|
| Spermidine powder -based CDs | Biogenic polyamines/ Pyrolysis | •Size = 6 nm | •Haemolymph of shrimp | For blocking receptor on host cell membrane using recombinant viral proteins or virus antiserum |
|
Figure 12Above: A schematic description of CDs on the photoexcited state processes, separating charge, trapping electrons, and creating holes and their radiative recombinations. Below: The energy transformation process with the obtained fluorescence quantum yield (ΦF). Reprinted with permission from the reference 83.